Related Experiment Video
Updated: Jul 13, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Disease modifying approaches for Alzheimer's pathology
Marcin Sadowski1, Thomas Wisniewski
1Department of Neurology, New York University School of Medicine, New York, NY 10016, USA.
Current Pharmaceutical Design
|July 14, 2007
Summary
Alzheimer's disease (AD) therapies targeting amyloid-beta show promise in mouse models. Early diagnosis is crucial, as preventing AD pathology is more feasible than clearing existing damage.
Area of Science:
- Neurodegenerative diseases
- Neuropathology
- Alzheimer's disease research
Background:
- Alzheimer's disease (AD) is a leading cause of age-related neurodegeneration.
- Key features include synaptic loss, neuronal loss, neurofibrillary tangles, and amyloid-beta (Abeta) deposition.
- Current research focuses on Abeta as a therapeutic target.
Purpose of the Study:
- To review the efficacy of Abeta-targeting therapies for Alzheimer's disease.
- To highlight the importance of early diagnosis and personalized treatment strategies for AD.
- To discuss the potential of multi-modal and tailored therapies for AD management.
Main Methods:
- Review of pre-clinical studies on Abeta-targeting therapeutic approaches.
- Analysis of data from transgenic mouse models of AD.
- Consideration of ongoing early-phase clinical trials for AD therapies.
Main Results:
- Abeta-targeting strategies have demonstrated success in preventing amyloid deposition and improving cognition in AD mouse models.
- Several Abeta-targeting therapies are progressing through early clinical trials.
- Pre-clinical evidence suggests preventing AD pathology is more achievable than clearing established pathology.
Conclusions:
- While promising, the clinical effectiveness of Abeta-targeting therapies in human patients requires further validation.
- Future Alzheimer's disease treatments will likely involve multi-modal approaches tailored to individual patient profiles, including immune status, genetics, and amyloid burden.
- Early diagnosis is paramount for effective AD prevention and management.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...